Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14179767 | 0.81 | TSHR (0.38) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL26554486 | 0.81 | OGA (0.38) | TSHREPHX1 | |
| SCHEMBL7951294 | 0.78 | TSHR (0.43) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL50998 | 0.78 | TSHR (0.43) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15298424 | 0.77 | SLC5A2 (0.44) | TSHR | |
| SCHEMBL26554087 | 0.76 | TSHR (0.40) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL25605622 | 0.74 | SLC6A4 (0.40) | SLC6A2HTR2BSLC6A3EPHX1HTR1A | |
| SCHEMBL16572175 | 0.70 | PDPK1 (0.37) | TSHRSLC6A2HTR1A | |
| Formic Acid SCHEMBL28886146 | 0.69 | TSHR (0.47) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL464421 | 0.69 | MEN1 (0.39) | TSHRMEN1KMT2ASMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | TSHR 2910/4885CHRM2 4723/4885CHRM4 4440/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | TSHR 2910/4885CHRM2 4723/4885CHRM4 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.